---
schema_version: "secwatch.filing_event.v1"
accession: "0001725160-26-000010"
form_type: "8-K"
ticker: "ZNTL"
cik: "0001725160"
company_name: "Zentalis Pharmaceuticals, Inc."
filed_at: "2026-03-26T23:59:59+00:00"
generated_at: "2026-05-15T08:51:32.273767+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Zentalis reports FY2025 results; cash $245.9M, DENALI Part 2 topline due year-end 2026

## Summary
- Cash, equivalents and marketable securities $245.9M as of Dec 31, 2025; projected runway into late 2027.
- R&D expenses $107.3M (down 36% YoY); G&A expenses $37.7M (down 57% YoY).
- DENALI Part 2a enrollment completed; monotherapy dose confirmation expected 1H 2026.
- DENALI Part 2 topline readout on track for year-end 2026; potential to support accelerated approval.
- ASPENOVA Phase 3 confirmatory trial (azenosertib vs chemo in Cyclin E1+ PROC) to initiate 1H 2026.

## SEC filing metadata
- accession: 0001725160-26-000010
- form_type: 8-K
- ticker: ZNTL
- cik: 0001725160
- company_name: Zentalis Pharmaceuticals, Inc.
- filed_at: 2026-03-26T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1725160/000172516026000010/0001725160-26-000010-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1725160/000172516026000010/zntl-20260326.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001725160-26-000010
- JSON: https://secwatch.observer/filing/0001725160-26-000010.json
- Plain text: https://secwatch.observer/filing/0001725160-26-000010.txt

## Key facts
- Earnings Releases
  Zentalis Pharmaceuticals, Inc. reported financial results for the year ended December 31, 2025.
  - Period: the year ended December 31, 2025
  - Result: reported results
  source text: On March 26, 2026, Zentalis Pharmaceuticals, Inc. (the “Company”) announced its financial results for the year ended December 31, 2025, and commented on certain business updates. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K (this "Current Report") and is incorporated herein by reference.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1725160/000172516026000010/0001725160-26-000010-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.